scholarly journals P13 Bronchial thermoplasty maintains a long-term reduction in peripheral blood eosinophils in severe asthma

Author(s):  
K Hince ◽  
LJ Holmes ◽  
G McCumesky ◽  
D Ryan ◽  
RM Niven
Thorax ◽  
2014 ◽  
Vol 69 (Suppl 2) ◽  
pp. A52-A52
Author(s):  
D. Ryan ◽  
L. Holmes ◽  
G. McCumesky ◽  
R. Daly ◽  
K. Hince ◽  
...  

2021 ◽  
pp. 2100622
Author(s):  
Nicholas Jendzjowsky ◽  
Austin Laing ◽  
Michelle Malig ◽  
John Matyas ◽  
Elaine de Heuvel ◽  
...  

RationaleBronchial thermoplasty is a mechanical therapeutic intervention that has been advocated as an effective treatment option for severe asthma. The mechanism is promoted as being related to the attenuation of airway smooth muscle which has been shown to occur in the short-term. However, long-term studies of the effects of bronchial thermoplasty on airway remodeling are few with only limited assessment of airway remodeling indices.ObjectivesTo evaluate the effect of bronchial thermoplasty on (a) airway epithelial and smooth muscle cells in culture, and (b), airway remodeling in patients with severe asthma who have been prescribed bronchial thermoplasty up to 12-months post-treatment.MethodsThe distribution of heat within the airway by bronchial thermoplasty was assessed in a porcine model. Culture of human airway smooth muscle cells and bronchial epithelial cells evaluated the impact of thermal injury. Histological evaluation and morphometric assessment were performed on bronchial biopsies obtained from severe asthma patients at baseline, 6-weeks, and 12-months following bronchial thermoplasty.ResultsBronchial thermoplasty resulted in heterogenous heating of the airway wall. Airway smooth muscle cell cultures sustained thermal injury, whilst bronchial epithelial cells were relatively resistant to heat. Airway smooth muscle and neural bundles were significantly reduced at 6-weeks and 12-months post-treatment. At 6-weeks post treatment, submucosal collagen was reduced, and vessel density increased, with both indices returning to baseline at 12-months. Goblet cell numbers, submucosal gland area and subbasement membrane thickness, were not significantly altered at any timepoint examined.ConclusionsBronchial thermoplasty primarily affects airway smooth muscle and nerves with the effects still present at 12-months post-treatment.


2014 ◽  
Vol 23 (134) ◽  
pp. 510-518 ◽  
Author(s):  
Marie-Christine Dombret ◽  
Khuder Alagha ◽  
Louis Philippe Boulet ◽  
Pierre Yves Brillet ◽  
Guy Joos ◽  
...  

Bronchial thermoplasty is a young yet promising treatment for severe asthma whose benefit for long-term asthma control outweighs the short-term risk of deterioration and hospitalisation in the days following the treatment. It is an innovative treatment whose clinical efficacy and safety are beginning to be better understood. Since this is a device-based therapy, the overall evaluation of risk–benefit is unlike that of pharmaceutical products; safety aspects, regulatory requirements, study design and effect size assessment may be unfamiliar. The mechanisms of action and optimal patient selection need to be addressed in further rigorous clinical and scientific studies. Bronchial thermoplasty fits in perfectly with the movement to expand personalised medicine in the field of chronic airway disorders. This is a device-based complimentary asthma treatment that must be supported and developed in order to meet the unmet needs of modern severe asthma management. The mechanisms of action and the type of patients that benefit from bronchial thermoplasty are the most important challenges for bronchial thermoplasty in the future.


2017 ◽  
Vol 50 (2) ◽  
pp. 1700017 ◽  
Author(s):  
Geoffrey Chupp ◽  
Michel Laviolette ◽  
Lauren Cohn ◽  
Charlene McEvoy ◽  
Sandeep Bansal ◽  
...  

Author(s):  
Jamila Chakir ◽  
Ikhlass Haj Salem ◽  
Louis-Philippe Boulet ◽  
Sabrina Biardel ◽  
Noel Lampron ◽  
...  

Author(s):  
Polliana Mihaela Leru

: Asthma is a complex and highly heterogeneous disorder, having many clinical phenotypes and underlining mechanisms, a broad spectrum of severity and variable response to controller therapy. Intensive research has been focused on identification and validation of the most appropriate biomarkers in the clinical management of asthma, mostly addressed to severe and refractory cases. The use of reliable biomarkers in severe asthma can contribute to better understanding of disease biology, diagnosis and screening, by a refined characterization of particular phenotypes and endotypes, assessment of severity, control and prognosis. There is an increasing interest to validate biomarkers able to indicate the adequate therapeutic choice from the class of biological agents, most of them targeting T2 inflammation. Using a reliable and validated biomarker, the clinician can monitor the response to initial therapy and early identify a severe phenotype. The aim of this paper is to review the clinical utility of relevant biomarkers currently used in asthma management. Indication for a more advanced and efficient therapy, such as monoclonal antibodies and selection of the optimal molecule is based on biomarkers and clinical criteria, according to the most recent experts’ recommendations. Peripheral blood eosinophils is considered an important biomarker for selection and identification of responders to anti-eosinophil biological therapy. Reallife long-term studies to confirm the precise use and cutoffs of the already approved biomarkers for T2 phenotypes and to identify reliable biomarkers for non- T2 severe asthma are still unmet needs in asthma management.


Sign in / Sign up

Export Citation Format

Share Document